The combination of chemotherapy and intraperitoneal MegaFas Ligand improves treatment of ovarian carcinoma

Gynecologic Oncology

Volumn 107, Issue 1, 2007, Pages 14-21

  Etter, Anne Lise ^a   Bassi, Isabelle ^a   Germain, Stéphane ^a   Delaloye, Jean François ^b   Tschopp, Jürg ^c   Sordat, Bernard ^a   Dupuis, Marc ^a  

^a Apoxis SA   (Switzerland)

^b LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^c UNIVERSITY OF LAUSANNE   (Switzerland)

Author keywords

Apoptosis; Fas; Intraperitoneal; Ovarian carcinoma

Indexed keywords

ANTIINFECTIVE AGENT; CISPLATIN; MEGAFAS LIGAND; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; ASCITES CELL; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CONTROLLED STUDY; CYTOTOXICITY; DISEASE SEVERITY; DRUG EFFICACY; DRUG MECHANISM; FEMALE; IN VITRO STUDY; IN VIVO STUDY; MONOTHERAPY; MOUSE; NONHUMAN; OVARY CARCINOMA; PRIORITY JOURNAL; STATISTICAL SIGNIFICANCE; XENOGRAFT;

ADIPONECTIN; ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; CELL LINE, TUMOR; CISPLATIN; COLLAGEN; DRUG EVALUATION; FAS LIGAND PROTEIN; FEMALE; HUMANS; INJECTIONS, INTRAPERITONEAL; MICE; OVARIAN NEOPLASMS; PROTEIN STRUCTURE, TERTIARY; RECOMBINANT FUSION PROTEINS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 34748887866     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2007.05.030     Document Type: Article

References (33)

1. Ashkenazi A. Targeting death and decoy receptors of the tumour-necrosis factor superfamily. Nat. Rev., Cancer 2 (2002) 420-430
2. Ashkenazi A., and Dixit V.M. Death receptors: signaling and modulation. Science 281 (1998) 1305-1308
3. Schneider P., and Tschopp J. Apoptosis induced by death receptors. Pharm. Acta Helv. 74 (2000) 281-286
4. El-Deiry W.S. Insights into cancer therapeutic design based on p53 and TRAIL receptor signaling. Cell. Death Differ. 8 (2001) 1066-1075
5. French L.E., and Tschopp J. Protein-based therapeutic approaches targeting death receptors. Cell. Death Differ. 10 (2003) 117-123
6. Cullen K.V., Davey R.A., and Davey M.W. Drug resistance does not correlate with resistance to Fas-mediated apoptosis. Leuk. Res. 25 (2001) 69-75
7. Trauth B.C., Klas C., Peters A.M., Matzku S., Moller P., Falk W., Debatin K.M., and Krammer P.H. Monoclonal antibody-mediated tumor regression by induction of apoptosis. Science 245 (1989) 301-305
8. Ogasawara J., Watanabe-Fukunaga R., Adachi M., Matsuzawa A., Kasugai T., Kitamura Y., Itoh N., Suda T., and Nagata S. Lethal effect of the anti-Fas antibody in mice. Nature 364 (1993) 806-809
9. Nagata S. Fas ligand-induced apoptosis. Annu. Rev. Genet. 33 (1999) 29-55
10. Shiraishi T., Suzuyama K., Okamoto H., Mineta T., Tabuchi K., Nakayama K., et al. Increased cytotoxicity of soluble Fas ligand by fusing isoleucine zipper motif. Biochem. Biophys. Res. Commun. 322 (2004) 197-202
11. Takayama H., Kojima H., and Shinohara N. Cytotoxic T lymphocytes: the newly identified Fas (CD95)-mediated killing mechanism and a novel aspect of their biological functions. Adv. Immunol. 60 (1995) 289-321
12. Stewart J.H.t., Nguyen D.M., Chen G.A., and Schrump D.S. Induction of apoptosis in malignant pleural mesothelioma cells by activation of the Fas (Apo-1/CD95) death-signal pathway. J. Thorac. Cardiovasc. Surg. 123 (2002) 295-302
13. Holler N., Tardivel A., Kovacsovics-Bankowski M., Hertig S., Gaide O., Martinon F., et al. Two adjacent trimeric Fas ligands are required for Fas signaling and formation of a death-inducing signaling complex. Mol. Cell. Biol. 23 (2003) 1428-1440
14. Massazza G., Tomasoni A., Lucchini V., Allavena P., Erba E., Colombo N., et al. Intraperitoneal and subcutaneous xenografts of human ovarian carcinoma in nude mice and their potential in experimental therapy. Int. J. Cancer 44 (1989) 494-500
15. Greaney P., Nahimana A., Lagopoulos L., Etter A.L., Aubry D., Attinger A., et al. A Fas agonist induces high levels of apoptosis in haematological malignancies. Leuk. Res. 30 (2006) 415-426
16. Hayakawa A., Wu J., Kawamoto Y., Zhou Y.W., Tanuma S., Nakashima I., et al. Activation of caspase-8 is critical for sensitivity to cytotoxic anti-Fas antibody-induced apoptosis in human ovarian cancer cells. Apoptosis 7 (2002) 107-113
17. Vignati S., Codegoni A., Polato F., and Broggini M. Trail activity in human ovarian cancer cells: potentiation of the action of cytotoxic drugs. Eur. J. Cancer 38 (2002) 177-183
18. Cuello M., Ettenberg S.A., Nau M.M., and Lipkowitz S. Synergistic induction of apoptosis by the combination of trail and chemotherapy in chemoresistant ovarian cancer cells. Gynecol. Oncol. 81 (2001) 380-390
19. Garofalo A., Naumova E., Manenti L., Ghilardi C., Ghisleni G., Caniatti M., et al. The combination of the tyrosine kinase receptor inhibitor SU6668 with paclitaxel affects ascites formation and tumor spread in ovarian carcinoma xenografts growing orthotopically. Clin. Cancer Res. 9 (2003) 3476-3485
20. Arts H.J., de Jong S., Hollema H., Ten Hoor K.A., de Vries E.G., and van der Zee A.G. Fas and Fas ligand in cyst fluids, serum and tumors of patients with benign and (borderline) malignant ovarian tumors. Int. J. Oncol. 26 (2005) 379-384
21. Arts H.J., de Jong S., Hollema H., ten Hoor K., van der Zee A.G., and de Vries E.G. Chemotherapy induces death receptor 5 in epithelial ovarian carcinoma. Gynecol. Oncol. 92 (2004) 794-800
22. Muller M., Wilder S., Bannasch D., Israeli D., Lehlbach K., Li-Weber M., et al. p53 activates the CD95 (APO-1/Fas) gene in response to DNA damage by anticancer drugs. J. Exp. Med. 188 (1998) 2033-2045
23. Nagane M., Pan G., Weddle J.J., Dixit V.M., Cavenee W.K., and Huang H.J. Increased death receptor 5 expression by chemotherapeutic agents in human gliomas causes synergistic cytotoxicity with tumor necrosis factor-related apoptosis-inducing ligand in vitro and in vivo. Cancer Res. 60 (2000) 847-853
24. Yaginuma Y., and Westphal H. Abnormal structure and expression of the p53 gene in human ovarian carcinoma cell lines. Cancer Res. 52 (1992) 4196-4199
25. Lacour S., Micheau O., Hammann A., Drouineaud V., Tschopp J., Solary E., et al. Chemotherapy enhances TNF-related apoptosis-inducing ligand DISC assembly in HT29 human colon cancer cells. Oncogene 22 (2003) 1807-1816
26. Delmas D., Rebe C., Lacour S., Filomenko R., Athias A., Gambert P., et al. Resveratrol-induced apoptosis is associated with Fas redistribution in the rafts and the formation of a death-inducing signaling complex in colon cancer cells. J. Biol. Chem. 278 (2003) 41482-41490
27. Lacour S., Hammann A., Grazide S., Lagadic-Gossmann D., Athias A., Sergent O., et al. Cisplatin-induced CD95 redistribution into membrane lipid rafts of HT29 human colon cancer cells. Cancer Res. 64 (2004) 3593-3598
28. du Bois A., Luck H.J., Meier W., Adams H.P., Mobus V., Costa S., et al. A randomized clinical trial of cisplatin/paclitaxel versus carboplatin/paclitaxel as first-line treatment of ovarian cancer. J. Natl. Cancer Inst. 95 (2003) 1320-1329
29. du Bois A., Weber B., Rochon J., Meier W., Goupil A., Olbricht S., et al. Addition of epirubicin as a third drug to carboplatin-paclitaxel in first-line treatment of advanced ovarian cancer: a prospectively randomized gynecologic cancer intergroup trial by the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group and the Groupe d'Investigateurs Nationaux pour l'Etude des Cancers Ovariens. J. Clin. Oncol. 24 (2006) 1127-1135
30. Ozols R.F., Bundy B.N., Greer B.E., Fowler J.M., Clarke-Pearson D., Burger R.A., et al. Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study. J. Clin. Oncol. 21 (2003) 3194-3200
31. Alberts D.S., Liu P.Y., Hannigan E.V., O'Toole R., Williams S.D., Young J.A., et al. Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer. N. Engl. J. Med. 335 (1996) 1950-1955
32. Armstrong D.K., Bundy B., Wenzel L., Huang H.Q., Baergen R., Lele S., et al. Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N. Engl. J. Med. 354 (2006) 34-43
33. Markman M., Bundy B.N., Alberts D.S., Fowler J.M., Clark-Pearson D.L., Carson L.F., et al. Phase III trial of standard-dose intravenous cisplatin plus paclitaxel versus moderately high-dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small-volume stage III ovarian carcinoma: an intergroup study of the Gynecologic Oncology Group, Southwestern Oncology Group, and Eastern Cooperative Oncology Group. J. Clin. Oncol. 19 (2001) 1001-1007